Literature DB >> 22611048

Immunohistochemical detection of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 in formalin-fixed breast carcinoma cell block preparations: correlation of results to corresponding tissue block (needle core and excision) samples.

Mary D Kinsella1, George G Birdsong, Momin T Siddiqui, Cynthia Cohen, Krisztina Z Hanley.   

Abstract

Evaluation of ER, PR and Her 2 are routinely performed on breast carcinomas. For accurate detection of these markers, compliance with the ASCO/CAP guidelines is recommended. Our previous study showed that alcohol fixation did not affect ER results when alcohol-fixed cell block (CB) sections were compared to formalin-fixed tissue sections, while PR and Her2 showed less concordance. The aim of this study was to evaluate and to compare ER, PR and Her2 IHC results on formalin-fixed CB sections to those observed on subsequent surgical (needle core or resection) specimens (SS). Fifty cases of formalin fixed CB samples obtained from primary (18%) and metastatic (82%) breast carcinomas were studied, all of which had subsequent SS available. ER, PR, and Her2 IHC studies were done on all samples and results were compared. ER results on formalin-fixed CB samples showed excellent correlation with SS (correlation coefficient cc = 0.82). While there was minimal improvement in PR results (cc = 0.433), Her2 detection did not improve by formalin fixation (cc = 0.439). Formalin fixation for CB preparations does not significantly improve the already good detection of ER positive breast tumors. The concordance rate in PR and IHC results between formalin-fixed CB and SS samples showed improvement as compared with the alcohol-fixed CB results. However, there was no improvement in detection of Her2 overexpression by using formalin fixation on cytology specimens.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22611048     DOI: 10.1002/dc.21815

Source DB:  PubMed          Journal:  Diagn Cytopathol        ISSN: 1097-0339            Impact factor:   1.582


  9 in total

Review 1.  HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.

Authors:  Angela N Bartley; Mary Kay Washington; Christina B Ventura; Nofisat Ismaila; Carol Colasacco; Al B Benson; Alfredo Carrato; Margaret L Gulley; Dhanpat Jain; Sanjay Kakar; Helen J Mackay; Catherine Streutker; Laura Tang; Megan Troxell; Jaffer A Ajani
Journal:  Am J Clin Pathol       Date:  2016-11-14       Impact factor: 2.493

2.  Cytologic assessment of estrogen receptor, progesterone receptor, and HER2 status in metastatic breast carcinoma.

Authors:  Fresia Pareja; Melissa P Murray; Ryan Des Jean; Fumiko Konno; Maria Friedlander; Oscar Lin; Marcia Edelweiss
Journal:  J Am Soc Cytopathol       Date:  2017 Jan-Feb

3.  Assessment of Hormone Receptor and Human Epidermal Growth Factor Receptor 2 Status in Breast Carcinoma Using Thin-Prep Cytology Fine Needle Aspiration Cytology FISH Experience From China.

Authors:  Zhihui Zhang; Peng Yuan; Huiqin Guo; Linlin Zhao; Jianming Ying; Mingrong Wang; Huan Zhao; Qinjing Pan; Binghe Xu
Journal:  Medicine (Baltimore)       Date:  2015-06       Impact factor: 1.889

4.  Identification of estrogen receptor proteins in breast cancer cells using matrix-assisted laser desorption/ionization time of flight mass spectrometry (Review).

Authors:  Zbynek Heger; Miguel Angel Merlos Rodrigo; Sona Krizkova; Ondrej Zitka; Miroslava Beklova; Rene Kizek; Vojtech Adam
Journal:  Oncol Lett       Date:  2014-02-26       Impact factor: 2.967

5.  Evaluating Estrogen Receptor Immunohistochemistry on Cell Blocks From Breast Cancer Patients in a Low-Resource Setting.

Authors:  Asteria H Kimambo; Edda A Vuhahula; Amos R Mwakigonja; Britt-Marie Ljung; Li Zhang; Katherine Van Loon; Dianna L Ng
Journal:  Arch Pathol Lab Med       Date:  2021-07-01       Impact factor: 5.686

6.  Fine-needle aspiration cytology can play a role in neoadjuvant chemotherapy in operable breast cancer.

Authors:  Christian Garbar; Hervé Curé
Journal:  ISRN Oncol       Date:  2013-07-10

7.  HER 2 immunohistochemistry for breast cancer cell blocks can be used in the same way as that used for histological specimens.

Authors:  Rieko Nishimura; Nami Okamoto; Masakazu Satou; Kenta Kojima; Shinichi Tanaka
Journal:  Diagn Cytopathol       Date:  2016-01-22       Impact factor: 1.582

8.  Bright-field HER2 dual in situ hybridization (DISH) assay on breast cancer cell blocks: a comparative study with histological sections.

Authors:  Rieko Nishimura; Nami Okamoto; Masakazu Satou; Kenta Kojima; Shinichi Tanaka; Natsumi Yamashita
Journal:  Breast Cancer       Date:  2016-01-08       Impact factor: 4.239

9.  Clinical significance of evaluating hormone receptor and HER2 protein using cell block against metastatic breast cancer: a multi-institutional study.

Authors:  Akira Matsui; Yuya Murata; Norikazu Masuda; Kiyoshi Mori; Masato Takahashi; Katsushige Yamashiro; Kenjirou Aogi; Shigeto Maeda; Masahiro Itou; Shinji Ozaki; Kazuya Kuraoka; Yasuyuki Satou; Shu Ichihara; Eriko Tokunaga; Kenichi Taguchi; Takanori Watanabe; Hiroyoshi Suzuki; Aiko Nagayama; Rieko Nishimura
Journal:  Oncotarget       Date:  2019-10-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.